Impact Therap-b (7630)の価格はいくらですか

Impact Therap-b (7630)の価格は$1.85です

Impact Therap-b (7630)の時価総額は何ですか

Impact Therap-b (7630)の時価総額は$510.85Mです

Impact Therap-b（7630）EPS（1株当たり利益）

IMPACT Therapeutics, a biotechnology firm, specializes in the discovery and advancement of precision anti-cancer treatments rooted in synthetic lethality, operating across China and international markets. The company's primary offering, Senaparib (IMP4297), is a PARP1/2 inhibitor currently deployed as a first-line maintenance therapy for ovarian cancer. Beyond this, Impact Therapeutics maintains a robust pipeline of investigational drugs. This includes IMP1734, a next-generation PARP1 selective inhibitor undergoing Phase I/II trials as a standalone treatment for advanced solid tumors. Another promising candidate is IMP9064, an ATR kinase selective inhibitor, also in Phase I/II clinical studies for advanced solid tumors as a monotherapy. IMP1707, a PARP1 selective inhibitor capable of penetrating the central nervous system, is in Phase I development for homologous recombination repair-deficient tumors. Additionally, IMP7068, an advanced WEE1 inhibitor, is progressing through Phase I/II clinical trials for various advanced solid tumors. Furthermore, a range of other compounds, namely IMP22, IMP25, IMP08, IMP13, IMP10, IMP27, and IMP32, are in the preclinical development phase. The company, established in 2009, is headquartered in Shanghai, China.

年	EPS	変化
提供された日付のデータは十分ではありません。

年

EPS

変化

提供された日付のデータは十分ではありません。

企業	EPS	EPSの差	国
Eli Lilly and Company LLY.US	$29.85	-	US
Johnson & Johnson JNJ.US	$8.65	-	US
AbbVie Inc. ABBV.US	$3.55	-	US
Roche Holding AG RO.SW	$20.39	-	CH
Merck & Co., Inc. MRK.US	$1.26	-	US

企業

EPS

EPSの差

国

Eli Lilly and Company

LLY.US

$29.85

Johnson & Johnson

JNJ.US

$8.65

AbbVie Inc.

ABBV.US

$3.55

Roche Holding AG

RO.SW

$20.39

Merck & Co., Inc.

MRK.US

$1.26

Impact Therap-b

7630

カテゴリー